English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

An open multicentre study was conducted at 18 Canadian centresin patients diagnosed as suffering from irritable bowel syndrome ((BS). One hundredand thirty-one (72%, female and 28% male) patients, mean age 44 years, weretreated with 200 mg tid trimebutine maleate (Modulon; Jouveinal) for periods offour weeks. Frequency and severity of pain, constipation and diarrhea were analyzed,as were stool frequency and consistency. A statistically significant reductionof frequency and severity was discerned in all symptoms (pain, constipation.diarrhea). Stool frequency foll within normal range (three per week to three per day)in close to 90% of patients as compared to 66% prior to the study. Similarly, stoolconsistency was normal in over 40% more patients at the end of the study thanbefore treatment. Global evaluation by physicians and patients showed that approximately70% of patients felt better at the end of the treatment than before the study.Side effects such as nausea, headaches and fatigue were reported in 14 patients.leadingto discontinuation of therapy in seven. In conclusion , trimebutine maleate waseffective in reducing the frequency and severity of the major symptoms of IBS aswell as in normalizing transit disturbances as measured by stool frequency

Trimebutine Maleate in the Treatment of Irritable Bowel Syndrome: Canadian Clinical Experience